Acute renal failure

被引:0
作者
Krych, M [1 ]
机构
[1] Univ Munich, Klinikum Grosshadern, Med Klin & Poliklin 3, D-81377 Munich, Germany
来源
INTERNIST | 2005年 / 46卷 / 01期
关键词
nephrotoxicity; acute renal failure; chemotherapy; tumor lysis syndrome; oncology;
D O I
10.1007/s00108-004-1316-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The acute renal failure is characterized by a rapid detoriation of the renal function. In addition to the usual prerenal, intrinsic and postrenal causes of an acute renal failure distinct causes have to be considered for oncological patients. Factors immanent to the malignant disease, e. g. paraneoplastic syndromes or retroperitoneal bulks can account for an acute renal failure. Paraproteins as produced by a multiple myeloma are other possible causes for renal dysfunction. For some anticancer drugs nephrotoxicity is a potential side effect, in particular for cisplatin, methotrexate, ifosfamide and melphalan. A hemolytic uremic syndrome may be induced by mitomycin and gemcitabine. Extensive surgery can be associated with rhabdonnyolysis and myoglobin-uria and results in renal impairment. Treatment of a chemosensitive neoplasia with a highly effective regimen may result in a tumor lysis syndrome with hyperuricemia, hyperkalemia, hyperphosphatemia and hypocalcemia.
引用
收藏
页码:30 / +
页数:8
相关论文
共 33 条
[11]   Malignancy and renal disease [J].
Kapoor, M ;
Chan, GZ .
CRITICAL CARE CLINICS, 2001, 17 (03) :571-+
[12]   CLINICAL VERSUS LABORATORY TUMOR LYSIS SYNDROME IN CHILDREN WITH ACUTE-LEUKEMIA [J].
KEDAR, A ;
GROW, W ;
NEIBERGER, RE .
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 1995, 12 (02) :129-134
[13]   Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites [J].
Kerbusch, T ;
de Kraker, J ;
Keizer, HJ ;
van Putten, JWG ;
Groen, HJM ;
Jansen, RLH ;
Schellens, JHM ;
Beijnen, JH .
CLINICAL PHARMACOKINETICS, 2001, 40 (01) :41-62
[14]  
Kern W, 2000, ANTICANCER RES, V20, P3679
[15]   ANTICANCER DRUG RENAL TOXICITY AND ELIMINATION - DOSING GUIDELINES FOR ALTERED RENAL-FUNCTION [J].
KINTZEL, PE ;
DORR, RT .
CANCER TREATMENT REVIEWS, 1995, 21 (01) :33-64
[16]   Anticancer drug-induced kidney disorders - Incidence, prevention and management [J].
Kintzel, PE .
DRUG SAFETY, 2001, 24 (01) :19-38
[17]   Prophylaxis and differential therapy of tumorlysis syndrome [J].
Krych, M ;
Dreyling, M ;
Kneba, M ;
Hoelzer, D ;
Hiddemann, W ;
Hallek, M .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2004, 129 (25-26) :1440-1445
[18]   Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant [J].
Lee, CK ;
Zangari, M ;
Barlogie, B ;
Fassas, A ;
van Rhee, F ;
Thertulien, R ;
Talamo, G ;
Muwalla, F ;
Anaissie, E ;
Hollmig, K ;
Tricot, G .
BONE MARROW TRANSPLANTATION, 2004, 33 (08) :823-828
[19]   The role of circulating immune complexes and biocompatibility of staphylococcal protein A immunoadsorption in mitomycin C-induced hemolytic uremic syndrome [J].
Mistry, B ;
Kimmel, PL ;
Hetzel, PC ;
Phillips, TM ;
Braden, GL .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2004, 44 (04) :e50-e58
[20]  
MOCKEL M, 2002, Z KARDIOL, V91, P179